Kann P H, Hadji P, Bergmann R S
Zentrum für Innere Medizin - Bereich Endokrinologie & Diabetologie, Philipps-Universität Marburg/Universitätsklinikum Marburg UKGM, 35033, Marburg, Deutschland,
Z Rheumatol. 2014 May;73(4):323-8. doi: 10.1007/s00393-013-1286-7.
[corrected] There are many drugs which can cause osteoporosis or at least favor its initiation. The effect of hormones and drugs with antihormonal activity, such as glucocorticoids and aromatase inhibitors, on initiation of osteoporosis is well known. In addition, proton pump inhibitors, glitazones and diuretics also influence the formation of osteoporosis.
The results of currently available studies on the correlation between proton pump inhibitors, glitazones and diuretics on formation of osteoporosis were evaluated and summarized.
Proton pump inhibitors and glitazones increase the risk for osteoporotic fractures. Loop diuretics may slightly increase fracture risk, whereas thiazides were shown to be osteoprotective by reducing fracture probability on a relevant scale.
Proton pump inhibitors should not be prescribed without serious consideration and then only as long as necessary. Alternatively, the administration of the less effective H2 antagonists should be considered when possible due to the reduction of acid secretion. Because the long-term intake of thiazides is associated with a clinically relevant reduction in the risk of fractures and they are economic and well-tolerated, prescription can be thoroughly recommended within the framework of differential diagnostic considerations in an appropriate clinical context. The briefly increased risk of falling immediately after starting diuretic therapy is the only point which needs to be considered.
[已修正] 有许多药物可导致骨质疏松症或至少促使其发病。激素及具有抗激素活性的药物(如糖皮质激素和芳香化酶抑制剂)对骨质疏松症发病的影响已为人熟知。此外,质子泵抑制剂、格列酮类药物和利尿剂也会影响骨质疏松症的形成。
对目前关于质子泵抑制剂、格列酮类药物和利尿剂与骨质疏松症形成之间相关性的现有研究结果进行评估和总结。
质子泵抑制剂和格列酮类药物会增加骨质疏松性骨折的风险。袢利尿剂可能会轻微增加骨折风险,而噻嗪类利尿剂通过在一定程度上降低骨折概率显示出具有骨质保护作用。
质子泵抑制剂不应在未经过认真考虑的情况下开具处方,且仅在必要时使用。或者,由于其能减少胃酸分泌,在可能的情况下应考虑使用效果稍差的H2拮抗剂。由于噻嗪类药物的长期服用与临床上显著降低骨折风险相关,且它们经济实惠且耐受性良好,因此在适当的临床背景下,在鉴别诊断的框架内可充分推荐使用。开始利尿治疗后立即出现的短暂跌倒风险增加是唯一需要考虑的点。